IL252610A0 - Methods and preparations for the treatment of cancer - Google Patents

Methods and preparations for the treatment of cancer

Info

Publication number
IL252610A0
IL252610A0 IL252610A IL25261017A IL252610A0 IL 252610 A0 IL252610 A0 IL 252610A0 IL 252610 A IL252610 A IL 252610A IL 25261017 A IL25261017 A IL 25261017A IL 252610 A0 IL252610 A0 IL 252610A0
Authority
IL
Israel
Prior art keywords
compositons
methods
treating cancer
cancer
treating
Prior art date
Application number
IL252610A
Other languages
English (en)
Hebrew (he)
Original Assignee
Roger Williams Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger Williams Hospital filed Critical Roger Williams Hospital
Publication of IL252610A0 publication Critical patent/IL252610A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL252610A 2014-12-02 2017-06-01 Methods and preparations for the treatment of cancer IL252610A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (1)

Publication Number Publication Date
IL252610A0 true IL252610A0 (en) 2017-07-31

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252610A IL252610A0 (en) 2014-12-02 2017-06-01 Methods and preparations for the treatment of cancer

Country Status (18)

Country Link
US (2) US9650428B2 (enExample)
EP (1) EP3227317A4 (enExample)
JP (1) JP2017537622A (enExample)
KR (1) KR20180041087A (enExample)
CN (1) CN107709353A (enExample)
AR (1) AR102879A1 (enExample)
AU (1) AU2015355084A1 (enExample)
BR (1) BR112017011771A2 (enExample)
CA (1) CA2969714A1 (enExample)
EA (1) EA201791210A1 (enExample)
HK (1) HK1251862A1 (enExample)
IL (1) IL252610A0 (enExample)
MX (1) MX2017007272A (enExample)
PH (1) PH12017501031A1 (enExample)
SG (2) SG10202103475XA (enExample)
TW (1) TW201636425A (enExample)
UY (1) UY36418A (enExample)
WO (1) WO2016089916A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
CN110615835A (zh) 2012-08-09 2019-12-27 利兰斯坦福初级大学董事会 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
US9650428B2 (en) 2014-12-02 2017-05-16 Roger Williams Hospital Methods and compositions for treating cancer
CN108026151B (zh) * 2015-06-19 2022-07-15 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
AU2016301932B2 (en) * 2015-08-05 2020-02-27 CellabMED Inc. Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
US20200095301A1 (en) * 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
CN111629736A (zh) * 2017-11-20 2020-09-04 罗杰威廉姆斯医疗中心以普拉斯派克特查特凯尔Rwmc有限责任公司许可 用于改善car-t细胞功能的组合物及其用途
KR102752985B1 (ko) 2017-12-20 2025-01-10 포세이다 테라퓨틱스, 인크. Vcar 조성물 및 사용 방법
WO2019144091A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
US11701405B2 (en) * 2018-01-26 2023-07-18 City Of Hope Chimeric antigen receptors and methods for reducing toxicity
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
US12404497B2 (en) 2018-06-01 2025-09-02 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
EP4097127A2 (en) * 2020-01-31 2022-12-07 City of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
EP4159237A4 (en) * 2020-05-28 2024-08-28 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
US20230322894A1 (en) * 2020-08-26 2023-10-12 The Regents Of The University Of California Methods and compositions for treating glioblastoma
EP4210727A4 (en) * 2020-09-11 2024-12-25 University of Georgia Research Foundation, Inc. COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTING AND TREATING INFLUENZA INFECTIONS
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO2001029233A2 (en) * 1999-10-20 2001-04-26 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
AU2003218236B2 (en) * 2002-03-01 2007-12-06 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
AU2005339587B2 (en) * 2005-11-16 2011-11-03 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
PT3006459T (pt) * 2008-08-26 2021-11-26 Hope City Método e composições para funcionamento melhorado de efetores antitumorais de células t
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
ME02670B (me) * 2010-03-26 2017-06-20 Memorial Sloan Kettering Cancer Center Antitela za MUC16 i metode za njihovu primenu
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
AU2014216130B2 (en) * 2013-02-15 2017-11-16 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
EP2968601A1 (en) * 2013-03-10 2016-01-20 Baylor College Of Medicine Chemotherapy-resistant immune cells
US10323077B2 (en) * 2014-02-10 2019-06-18 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
US9650428B2 (en) 2014-12-02 2017-05-16 Roger Williams Hospital Methods and compositions for treating cancer

Also Published As

Publication number Publication date
EP3227317A4 (en) 2018-04-25
PH12017501031A1 (en) 2017-11-27
EA201791210A1 (ru) 2017-11-30
AR102879A1 (es) 2017-03-29
WO2016089916A1 (en) 2016-06-09
UY36418A (es) 2016-06-30
MX2017007272A (es) 2018-06-06
US9650428B2 (en) 2017-05-16
EP3227317A1 (en) 2017-10-11
CA2969714A1 (en) 2016-06-09
SG10202103475XA (en) 2021-05-28
US20160151490A1 (en) 2016-06-02
CN107709353A (zh) 2018-02-16
US20180072789A1 (en) 2018-03-15
KR20180041087A (ko) 2018-04-23
JP2017537622A (ja) 2017-12-21
AU2015355084A1 (en) 2017-06-29
SG11201704519YA (en) 2017-07-28
BR112017011771A2 (pt) 2018-07-10
HK1251862A1 (zh) 2019-04-26
TW201636425A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL323396A (en) Cancer treatment methods
IL252610A0 (en) Methods and preparations for the treatment of cancer
IL289947A (en) A method for treating cancer
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
EP3177292A4 (en) Compounds and methods for treating cancer
SMT202100273T1 (it) Metodi e composizioni per il trattamento del cancro
IL256523A (en) Compositions and methods for treating cancer
IL256836B (en) Methods for treating cancer using apilimod
IL255022A0 (en) Cancer treatment methods
IL247859A0 (en) Cancer treatment
IL255638A (en) Compositions and methods for treating cancer
IL246558A0 (en) New methods of cancer treatment
IL255018A0 (en) Cancer treatment methods
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL255016A0 (en) Cancer treatment methods
IL256763A (en) Compositions and methods for treating cancer
EP3160591A4 (en) Compositions and methods for treating cancer
GB201414904D0 (en) Materials and methods for treating cancer
GB201418640D0 (en) Agents and methods for treatment of cancer